|
|
|
|
|
亞旭所代理的MedChemExpress (MCE) 提供多元的高品質研究化學品和生物化學品，包括用於實驗室和科學用途的新型生物活性化合物、染劑、胜肽和天然化合物。
|
|
|
• 超過 30,000 種生物活性分子化合物的庫存
|
|
|
• 超過針對 20 多種信號通路中的 500 多種關鍵目標蛋白的化合物
|
|
• 產品均附上品質報告書（LC/MS、NMR 和 HPLC）
|
|
• 每月發布超過500 種最新的產品
|
|
• 提供詳細Datasheet的資訊
|
|
|
• 高純度和有競爭力的價格
|
|
|
• 快速到貨
|
|
|
|
CAS No.: 2621928-55-8
|
|
|
|
|
Research Area: KRAS G12D Inhibitor/Diverse Cancers
|
|
|
|
•
|
Noncovalent, potent, and selective KRAS G12D inhibitor (KD=0.2 pM).
|
|
•
|
Inhibits mutant KRAS-dependent signal and selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells.
|
|
•
|
Efficacious in a KRAS G12D mutant xenograft mouse tumor model.
|
|
|
|
Solubility: DMSO : 50 mg/mL (83.25 mM; Need ultrasonic)
|
|
|
|
|
|
|
Research Area: HDAC Inhibitor/Prostate Cancer/Cholangiocarcinoma
|
|
|
|
•
|
An orally active, potent hydroxamate-based pan-HDAC inhibitor with antitumor effects.
|
|
•
|
Enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine and 5-FU, thereby decreasing cell viability and inducing apoptosis.
|
|
•
|
Inhibits deacetylation of histone H3 and tubulin in prostate cancer cells and induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
|
|
|
|
Solubility: DMSO : 50 mg/mL (105.58 mM; Need ultrasonic)
H2O : 50 mg/mL (105.58 mM; Need ultrasonic)
|
|
|
|
CAS No.: 1352914-52-3
|
|
|
|
|
Research Area:
eIF4A Inhibitor/Neuroblastoma/Pancreatic Ductal Adenocarcinoma
|
|
|
|
•
|
A synthetic Rocaglate and potent eIF4A inhibitor with anticancer and antimalarial activities.
|
|
•
|
Exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis.
|
|
•
|
Induces apoptosis of neuroblastoma and gallbladder cancer cells.
|
|
|
|
Solubility: DMSO : 230 mg/mL (453.18 mM; Need ultrasonic)
|
|
|
|
|
|
|
Research Area: PRMT5•MTA Inhibitor/MTAP-del Cancer
|
|
|
|
•
|
A synthetic lethal-based orally active PRMT5•MTA inhibitor.
|
|
•
|
Selectively inhibits symmetric dimethylarginine (SDMA) marks and shows selective antitumor activity in MTAP-del tumor cells while sparing MTAP-WT cells.
|
|
|
|
Solubility: DMSO : 90 mg/mL (195.27 mM; Need ultrasonic)
H2O : 40 mg/mL (86.79 mM; Need ultrasonic)
|
|
|
|
CAS No.: 357425-68-4
|
|
|
|
|
Research Area: α3β4 nAChR Agonist/Alcohol Dependence
|
|
|
|
•
|
High-affinity partial agonist at α3β4 nAChR (Ki=21 nM; EC50=~3 μM), has the same high-binding affinity at α4β2 nAChR (Ki=21 nM) and can penetrate the CNS.
|
|
•
|
Selectively decreases ethanol but not sucrose consumption and operant self-administration following long-term exposure.
|
|
|
|
Solubility: DMSO : 200 mg/mL (880.17 mM; Need ultrasonic)
|
|
|
|
CAS No.: 245520-69-8
|
|
|
|
|
Research Area: PAR1 Antagonist/Myocardial Ischemia/Reperfusion Injury
|
|
|
|
•
|
Highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist.
|
|
•
|
Inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 (IC50=70 nM; Ki=35 nM) and inhibits thrombin-induced platelet aggregation (IC50=3 μM).
|
|
•
|
Limits myocardial ischemia/reperfusion injury in rat hearts.
|
|
|
|
Solubility: DMSO : 50 mg/mL (134.60 mM; Need ultrasonic)
|
|
|
Kinase 篩選服務
|
|
|
|
|
Kinase在新陳代謝、細胞信號傳導、蛋白質調節、細胞運輸、分泌過程和許多其他細胞路徑中至關重要，這使Kinase成為細胞功能的關鍵調節劑。 如果Kinase發生問題則會導致多種人類疾病的發生， 因此Kinase具有潛力可做為藥物的靶點。 然而真核生物Kinase（尤其是催化結構域）的高度保留結構給開發抑製劑帶來了巨大挑戰。 對於許多人來說，廣泛的分析需要新的Kinase抑制劑，進而了解kinase的結構與活性之間的關係。
MCE可以提供高品質和全面的Kinase檢測平台，其化合物和Kinase之間結合親和力/活性差異的實驗數據可以評估化合物的靶標選擇性。
|
|
|
主要特色:
|
|
•
|
品項齊全：400 多種Kinase，包括 AGC、CAMK、CMGC、CK1、STE、TK、TKL 和常見突變體。
|
|
•
|
靈活且可客製化的Kinase panel：Characteristic TK, CDK kinase profiles, 60/207/302 kinase panels和客製化 panels.
|
|
•
|
多種檢測：TR-FRET（LANCE Ultra、LathaScreen、HTRF）、螢光法（Kinase-Glo、ADP-Glo）、Z`-LYTE、binding assay。
|
|
•
|
檢測準確，快速服務。
|
|
|
|
|
|
|
|
|
|
|
|
MCE提供優質且便宜的Targeted Diversity Library以進行全面篩選
|
|
•
|
包括2,400多種化合物，涵蓋1,000多種異構體
|
|
•
|
為每個目標和異構體選擇了 1-3 種具有高效力和選擇性的化合物。
|
|
•
|
提供詳細的生物活性資料
|
|
•
|
具有全面靶標覆蓋的小分子化合物。
|
|
•
|
用於表型篩選的工具。
|
|
|
|
近期引用 MCE 產品的文獻
|
|
Nat Nanotechnol.
2021 Nov;16(11):1260-1270.
|
|
|
|
Cell Metab.
2021 Nov 2;33(11):2247-2259.e6.
|
|
|
|
Cell Metab.
2021 Dec 7;33(12):2355-2366.e8.
|
|
|
|
Cancer Cell.
2021 Nov 8;39(11):1531-1547.e10.
|
|
|
|
|
|
|
|
|
|
|
|
|
